BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BI 770371 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BI 770371\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06806852-2393@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:BI 770371: Phase 1 readout est. (NCT06806852)
DESCRIPTION:BI 770371\, phase 1.\nStudy: A Study to Test Whether Treatment 
 With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab
  Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone\
 nEstimated primary completion: 31 August 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/bi-770371#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06806852
URL:https://assetmemo.bio/drug/bi-770371#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
